Medical policy governing coverage and medical necessity criteria for intensity-modulated radiation therapy (IMRT) for individuals aged 19 and older in the state of Ohio; applies to UnitedHealthcare Ohio plans.
Change TypeMaterial revisions to covered indicationscoding and documentation updates
Effective DateMay 1, 2026
Next Review DateN/A
Key ActionWhen requesting authorization, specify treatment technique, indication, and image-guidance and include medical record documentation that supports medical necessity.
Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary, including replacing phrasing for breast cancer criteria and adding multiple cancer types and scenarios.
Added specific indications: hepatocellular carcinoma (unresectable), Hodgkin lymphoma, intrahepatic cholangiocarcinoma (unresectable), rectal cancer when treatment involves inguinal lymph nodes, limited-stage small cell lung cancer, retroperitoneal/intra-abdominal soft tissue sarcoma, and Stage I-II NSCLC undergoing hypofractionated RT up to 10 fractions.
Changed language regarding hippocampal-avoidance whole brain radiation therapy to state it is 'considered proven and medically necessary' for up to 10 fractions when all listed criteria are met.
Replaced permissive language that IMRT 'may be covered' for conditions not listed with 'may be considered medically necessary' for such conditions including recurrences or metastases in selected cases.
Removed language indicating compensator-based beam modulation is proven and medically necessary when combined with an IMRT indication listed as proven.
Added CPT codes 77407 and 77412 to Applicable Codes.
Removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017 from Applicable Codes.
Added language that medical records documentation may be required to assess clinical criteria and that documentation must support medical necessity.
Updated Description of Services, Clinical Evidence, and References sections to reflect current information.
Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary; several new indications added and wording clarified for breast and head and neck cancer listings.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
May 1, 2026effective date
19+policy applies to individuals age
Ohio-onlygeographic applicability
8New/added proven indications
2CPT codes added
5CPT/HCPCS codes removed
Coverage and Medical Necessity Criteria
Covered indications
IMRT is considered proven and medically necessary for definitive therapy of the primary site for the following conditions when treating individuals 19 years of age or older:
Listed tumor sites: Anus/anal canal; Breast cancer when any of the following criteria are met: left-sided internal mammary nodes are being treated OR accelerated partial-breast irradiation of up to five fractions; Central nervous system tumors (brain, brainstem, spinal cord), including benign; Cervical cancer; Endometrial cancer; Esophageal cancer; Head and neck cancers (including lymphoma and solitary plasmacytomas) when treatment includes pharynx (nasopharynx, oropharynx, hypopharynx), larynx, salivary glands, oral cavity (including tongue), nasal cavity, paranasal sinuses; Hepatocellular carcinoma, unresectable; Intrahepatic cholangiocarcinoma, unresectable; Hodgkin lymphoma; Mediastinal tumors (e.g., lymphomas, thyroid, thymomas, tracheal cancer); Non-small cell lung cancer when Stage I–II undergo hypofractionated RT up to 10 fractions OR Stage III undergoing chemoradiation; Pancreatic cancer; Prostate cancer; Rectal cancer when treatment involves inguinal lymph nodes; Small cell lung cancer, limited stage; Soft tissue sarcoma, retroperitoneal/intra-abdominal; Vulvar cancer
Hippocampal-avoidance whole brain RT: Hippocampal-avoidance whole brain radiation therapy of up to 10 fractions is considered proven and medically necessary when ALL are met: brain metastasis; ECOG performance status ≤ 2 or Karnofsky ≥ 70; prognosis ≥ 4 months; absence of leptomeningeal disease.up to 10 fractions
Exceptions/selected cases: IMRT may be considered medically necessary for conditions not listed above, including recurrences or metastases, on a case-by-case basis when at least ONE is present: (1) a non-IMRT technique with a clinically appropriate dose would increase clinically meaningful normal tissue toxicity as demonstrated by a comparison of IMRT and non-IMRT treatment plans; OR (2) the same or immediately adjacent area has been previously irradiated and IMRT is needed to sculpt dose to avoid exceeding cumulative normal tissue tolerance.
Unproven / Not Medically Necessary
Not medically necessary / unproven:
Unproven: IMRT used in conjunction with proton beam radiation therapy is considered unproven and not medically necessary due to insufficient evidence of efficacy.
Covered when supported by condition-specific guideline/trial evidence
Guideline and trial-supported indications and outcomes for IMRT and related advanced RT techniques
Anal cancer - definitive chemoradiation: Dose-painted IMRT (DP-IMRT) with concurrent 5FU/MMC is supported by RTOG 0529 data showing reductions in select acute and late toxicities without compromising long-term local control; ASTRO, ESMO, and NCCN recommend IMRT/VMAT for anal cancer with daily image guidance and QA.
RTOG 0529 long-term outcomes support similar efficacy with reduced late effects.
Breast cancer - APBI and IMRT-DIBH: APBI delivered with IMRT in selected low-risk patients demonstrated low ipsilateral breast tumor recurrence and reduced acute toxicity in randomized trials (e.g., Florence trial, ASTRO APBI guideline); IMRT combined with DIBH can reduce cardiac and pulmonary doses when treating left-sided disease and internal mammary nodes.
Fractionation examples: 30 Gy in 5 fractions for APBI per Florence; ASTRO recommends APBI regimens including 3,000 cGy in five once-daily fractions.
PMRT guidance: ASTRO/ASCO/SSO guidelines recommend PMRT for node-positive disease, pT4 disease, and ypN+ after neoadjuvant therapy, with treatment of chest wall/reconstructed breast and regional nodes; IMRT/VMAT is recommended when 3D-CRT cannot meet target coverage or OAR constraints, with daily image guidance and DIBH when beneficial.
PMRT indications and technique
Clinical recommendations from ASTRO/ASCO/SSO for postmastectomy radiation therapy (PMRT) and technique selection
PMRT recommended indications: PMRT is recommended for patients with node-positive (pN+) disease, any pT4 disease, initial cT4 or cN2-3 after neoadjuvant therapy regardless of pathologic response, and ypN+ after neoadjuvant therapy.
Strength: strong; quality: high to moderate
Target volumes: Treat ipsilateral chest wall/reconstructed breast and regional lymphatics (at-risk axillary, supra-/infraclavicular, internal mammary nodes); internal mammary node coverage may be individualized based on tumor location, size, and nodal burden.
Fractionation and technique: Moderate hypofractionation is recommended for PMRT in patients without reconstruction; for patients with reconstruction moderate hypofractionation or conventional fractionation are options. IMRT/VMAT recommended when 3D-CRT cannot meet targets or OAR constraints; daily image guidance and DIBH are recommended when they reduce heart/lung dose.
Strength: strong; evidence quality moderate to high
CNS tumor technique recommendations
CNS tumor recommendations regarding technique
WHO grade 4 diffuse glioma: ASTRO recommends IMRT/VMAT over 3D-CRT to reduce toxicity for WHO grade 4 diffuse glioma.
Strength: strong; quality: moderate
IDH-mutant grade 2/3 glioma: For IDH-mutant grade 2 and 3 diffuse glioma, IMRT/VMAT is strongly recommended to reduce acute and late toxicity; when unavailable, 3D-CRT is recommended.
Cervical cancer coverage rationale
Cervical cancer evidence and guideline-based stance on IMRT
Comparative outcomes: Randomized trials and meta-analyses (e.g., PARCER, Padhi, Lin meta-analysis) demonstrate that IMRT reduces acute and late GI/GU toxicities compared with 3D-CRT while maintaining similar pelvic tumor control and survival.
PARCER: 3-year grade ≥2 late GI toxicity-free survival 78% (IMRT) vs 57% (3D-CRT).
When IMRT is preferred: IMRT/IGRT is preferred for definitive or postoperative pelvic radiation to minimize GI and hematologic toxicity, for para-aortic node coverage, and when high-dose treatment to gross nodal disease is required; IGRT is essential to ensure target coverage and OAR sparing.
Supported by ASTRO, ESGO/ESTRO/ESP, NCCN
Brachytherapy note: IMRT should not routinely replace brachytherapy for central disease in patients with an intact cervix; brachytherapy remains essential for central disease control.
NCCN caution
Covered with clinical criteria
Guideline-based preferred use and indications
Gynecologic (cervical, endometrial): IMRT/VMAT is preferred over 3D-CRT for definitive and adjuvant pelvic radiotherapy to reduce dose to OARs and minimize GI and hematologic toxicity; IGRT is recommended for IMRT delivery; IMRT should not replace brachytherapy for central disease in patients with an intact cervix.
Supported by ESGO/ESTRO/ESP, ASTRO, NCCN, ACR
Esophageal cancer: IMRT (or PBRT) may be used when minimizing dose to heart and lungs is necessary; IMRT is increasingly standard in preoperative, definitive, and postoperative settings and may reduce pneumonitis and improve outcomes in some analyses.
Supported by RCTs and NCCN guidance
Head and neck (pharyngeal) tumors: Dysphagia-optimized IMRT (DO-IMRT) can improve patient-reported swallowing function compared with standard IMRT and reduce dose to pharyngeal constrictors, supported by randomized data.
Nutting DO-IMRT RCT showed improved MDADI scores at 12 and 24 months.
Technique vs dose considerations
Evidence on dose escalation
Dose escalation in esophageal cancer: Dose escalation to 61.6 Gy did not improve local control or survival compared with standard 50.4 Gy in a randomized trial (Hulshof et al.) and is not supported for routine escalation of primary tumor dose.
Impacts dose selection but does not directly mandate technique choice.
Indications supported by evidence/guidelines
Consider IMRT when ALL of the following apply (clinical rationale from trials and guidelines):
Site and intent: Tumor site and treatment intent align with guideline recommendations (e.g., postoperative oropharynx per ASTRO; nasopharynx, oropharynx, paranasal sinuses, salivary glands per NCCN).
References: ASTRO, NCCN
Organ-sparing need: There is clinical need to spare critical OARs (parotid glands, pharyngeal constrictors, mandible, cochlea, optic structures, heart, lungs, bowel) to reduce long-term toxicity.
Supported by RCTs and comparative studies showing reduced xerostomia and improved swallowing with IMRT.
Technical feasibility: IMRT planning can achieve required OAR dose constraints and is feasible given tumor location, motion management, and prior radiation history.
Guideline and planning comparisons note IMRT/VMAT/helical-IMRT may offer better sparing; use IGRT for verification.
Guideline-supported coverage criteria
Covered when supported by guideline-recommended indications and technical considerations
Head and neck: IMRT is preferred for several head and neck tumor sites to limit dose to critical structures and reduce long-term side effects; use at treating physician discretion for other sites.
NCCN preference cited
Hepatocellular carcinoma (HCC): EBRT modalities including IMRT may be used for unresectable or medically inoperable HCC; choice of fractionation and modality should consider liver function and tumor location; IMRT delivered in at least 10 fractions is the modality evaluated in systematic reviews.at least 10 fractions
ASTRO and NCCN recommendations cited
Intrahepatic cholangiocarcinoma (IHC): For unresectable IHC, induction chemotherapy followed by EBRT consolidation is recommended; dose-escalated EBRT (BED > 80.5 Gy) is associated with improved local control and OS in retrospective data and IMRT or proton therapy may be used for dose-escalated regimens.
Appropriateness of advanced radiotherapy modalities
Advanced radiation techniques are considered appropriate when ALL of the following apply:
General appropriateness: Technique selection (IMRT/VMAT/IGRT/DIBH/PBRT) is appropriate when it significantly decreases normal tissue exposure without compromising tumor coverage.
Per ILROG and NCCN guidance; individualization required
Clinical scenarios favoring advanced techniques: Complex anatomy (large anterior mediastinal PTV, proximity to heart/lungs/spinal cord), re-irradiation settings, young patients with long expected survival, or need to minimize specific OAR dose favor advanced techniques.
References: ILROG, NCCN
Minimum simulation standard for thymic tumors: CT-based 3D-CRT is the minimum; advanced imaging (4D-CT, PET/CT) and motion management should be used when needed.
Per NCCN for thymomas/thymic carcinoma
Evidence-based coverage considerations
Selected evidence indicates benefits and trade-offs of IMRT/VMAT vs 3D-CRT:
NSCLC evidence: Secondary analyses (NRG/RTOG 0617) and retrospective series report lower heart doses and reduced high-grade pneumonitis with IMRT versus 3D-CRT while maintaining similar survival and tumor control.
Supports technique selection to reduce cardiopulmonary toxicity.
Lymphoma evidence: In mediastinal Hodgkin lymphoma, VMAT/IMRT can reduce cardiac dose and valvular disease risk but may increase low-dose lung exposure—personalized planning is required.
Filippi et al. comparative dosimetric data
Pancreatic cancer evidence: IMRT is associated with lower rates of acute and late GI toxicity compared with 3D-CRT while maintaining similar OS/PFS in retrospective and systematic reviews.
Umezawa et al.; Bittner systematic review
Covered when clinically indicated per tumor-specific evidence and guideline recommendations
Evidence-based findings and guideline recommendations reported in this section:
Pancreatic cancer: IMRT reduces dose to stomach/duodenum and is associated with lower acute GI toxicity versus 3D-CRT; ASTRO recommends modulated techniques for localized pancreatic cancer.
Supports preferential use of IMRT to reduce GI toxicity where appropriate.
Prostate cancer: IMRT is associated with lower acute and late GU/GI toxicities versus 3D-CRT and provides acceptable long-term tumor control with dose escalation and hypofractionation; professional societies endorse IMRT as standard for many prostate indications.
ACR/AUA/ASTRO guidance supports IMRT use.
Rectal cancer: Meta-analytic and retrospective data show IMRT reduces grade ≥2 acute GI and GU toxicities versus 3D-CRT in neoadjuvant chemoradiotherapy; ASTRO conditionally recommends IMRT/VMAT and daily image guidance in selected scenarios.
Wee et al. meta-analysis and ASTRO guideline.
Covered with criteria — IMRT clinical indications and parameters
Covered when ALL of the following are met (guideline-supported scenarios where IMRT is appropriate):
Primary clinical indications: IMRT (including VMAT and IGRT) is appropriate when it provides better target coverage and/or normal tissue sparing compared with 3D conformal techniques, including for unresectable node-positive limited-stage SCLC, localized extremity/truncal soft tissue sarcoma (preoperative or postoperative), retroperitoneal sarcoma receiving preoperative radiation, vulvar cancer where IMRT allows OAR sparing, and stage I–II NSCLC treated with hypofractionation up to 10 fractions.
Fractionation options for LS-SCLC: Acceptable regimens include twice-daily 45 Gy in 1.5-Gy fractions OR once-daily 60–70 Gy in 1.8–2 Gy fractions when patients can tolerate definitive therapy.
ASTRO/ARS guideline recommendations.
Adjunct techniques: Use motion management, daily image guidance, and advanced simulation (eg, 4D-CT, PET/CT) when appropriate to account for tumor motion and anatomical changes during treatment.
Definitive Therapy — Proven and Medically Necessary Indications (summary)
Revised proven and medically necessary indications for IMRT (Definitive Therapy) include the following added and revised items:
Added proven indications: Hepatocellular carcinoma (unresectable); Hodgkin lymphoma; Intrahepatic cholangiocarcinoma (unresectable); Rectal cancer when treatment involves inguinal lymph nodes; Small cell lung cancer, limited stage; Soft tissue sarcoma, retroperitoneal/intra-abdominal; Stage I–II non-small cell lung cancer undergoing hypofractionated RT up to 10 fractions; and clarified breast and head and neck listings.
From Summary of Changes (05/01/2026).
Hippocampal-avoidance Whole Brain RT
HA-WBRT statements and criteria
HA-WBRT eligibility: Hippocampal-avoidance WBRT (up to 10 fractions) is considered proven and medically necessary when all listed criteria are met, including absence of metastases within the hippocampal-avoidance region and an expected prognosis of ≥ 4 months; HA-WBRT is typically delivered with memantine per guidelines (e.g., 30 Gy in 10 fractions per NCCN).up to 10 fractions
NRG CC001 and NCCN guidance support cognitive benefit and dosing; exclusion if hippocampal lesions present within ~5 mm.
Considered/Selected Cases
Non-listed conditions that may be considered medically necessary in selected cases:
Selected cases: IMRT may be considered medically necessary for conditions not defined as proven in the policy, including recurrences or metastases, when individualized justification is provided and one of the specified criteria (plan comparison showing reduced OAR dose or prior adjacent irradiation requiring sculpting to meet cumulative tolerance) is met.
Requests evaluated case-by-case; policy language updated to 'considered medically necessary'.
Revised summary of proven indications for IMRT definitive therapy (overview):
Proven and medically necessary indications (summary): Policy revised to explicitly list tumor types and scenarios considered proven and medically necessary for IMRT definitive therapy, including hepatocellular carcinoma unresectable; Hodgkin lymphoma; intrahepatic cholangiocarcinoma unresectable; rectal cancer when inguinal nodes are treated; limited-stage small cell lung cancer; retroperitoneal/intra-abdominal soft tissue sarcoma; stage I–II NSCLC using hypofractionation up to 10 fractions; and clarified breast and head and neck criteria.
See full policy body for individual indication details.
Considered Medical Necessity for Unlisted Conditions
Policy on unlisted conditions: IMRT may be considered medically necessary for a condition not defined as proven and medically necessary in the policy, including recurrences or metastases in selected cases; such requests will be evaluated case-by-case and require documentation demonstrating the rationale (e.g., comparative planning or prior radiation history).
Documentation requirement and case-by-case evaluation per policy.
Hippocampal-avoidance Whole Brain RT
HA-WBRT eligibility and fractionation limit: Hippocampal-avoidance whole brain radiation therapy of up to 10 fractions is considered proven and medically necessary when all listed criteria are met (no metastases within hippocampal-avoidance region, expected survival ≥ 4 months, ECOG ≤2 or KPS ≥70, absence of leptomeningeal disease); typical dosing per guidelines is 30 Gy in 10 fractions with memantine.up to 10 fractions
NRG CC001 and NCCN references cited.
This Medical Policy applies only to the state of Ohio. Requests for services that are stated as unproven or that exceed coverage or quantity limits will be evaluated for medical necessity in accordance with Ohio Administrative Code 5160-101.
Accelerated partial-breast irradiation (APBI) delivered with IMRT has randomized-trial data showing low ipsilateral breast tumor recurrence in selected low-risk patients (for example, the Florence trial with long-term follow-up), but technique and fractionation matter. The large NSABP B-39/RTOG 0413 equivalence trial did not meet equivalence of APBI to whole-breast irradiation overall, and some APBI schedules have been associated with higher late toxicity or worse cosmetic outcomes; therefore APBI-IMRT should be applied only in appropriately selected patients and with attention to technique and fractionation.
Routine substitution of external-beam IMRT for brachytherapy is not recommended for central cervical disease. Brachytherapy remains an essential component for control of central disease in patients with an intact cervix, and replacing brachytherapy with IMRT without strong clinical justification may be excluded from coverage.
For patients with an intact cervix and central disease, IMRT should not be used routinely as a substitute for brachytherapy. Coverage decisions may require justification when brachytherapy is omitted, as brachytherapy is preferred to achieve necessary central dose for disease control.
The glottic IMRT meta-analysis excluded several study types from pooled analysis (including case reports, systematic reviews, database analyses, non-English publications, studies lacking full-text access, and studies of neoadjuvant/adjuvant IMRT, recurrent/metastatic disease, reirradiation, or SBRT). These exclusions should be considered when interpreting pooled local control and toxicity estimates.
Hippocampal-avoidance whole brain radiation therapy (HA-WBRT) is not appropriate when metastases are located within the hippocampal-avoidance region (approximately within a 3–7 mm margin of the hippocampus) or in the setting of leptomeningeal disease. Eligibility for HA-WBRT also requires absence of hippocampal lesions and sufficient prognosis (commonly cited as ≥ 4 months) to expect cognitive preservation benefits.
High-dose radiation regimens beyond established standards have shown harm in randomized data and therefore require clear clinical justification. For example, analyses of RTOG 0617 and related work found that very high dose chemoradiation regimens did not improve outcomes and were associated with worse quality-of-life measures; dose-escalation decisions should be justified and documented rather than applied routinely.
No evidence was identified to support combining IMRT and proton beam radiation therapy in a single treatment plan. Plans proposing concurrent or combined IMRT and proton modalities lack supportive clinical evidence and may not be considered medically necessary.
Earlier policy language that referenced compensator-based beam modulation was removed from the current coverage criteria. This reflects a change from historic permissive wording and should not be interpreted as maintaining compensator-based language in the present policy.
Previous language that stated compensator-based beam modulation combined with IMRT indications was proven and medically necessary has been removed. The policy no longer asserts that compensator-based beam modulation plus IMRT is an independently proven, covered combination.
The policy specifies that IMRT delivered in combination with proton beam radiation therapy is considered unproven and not medically necessary due to insufficient evidence. Proposals to combine photon IMRT and proton modalities in a single treatment plan are not supported by the evidence cited in this policy.
Applicable Procedure and Billing Codes
Applicable procedure codes (reference)CPT
77301
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77387
Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77407
Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed.
77412
Radiation treatment delivery; Level 3, multiple isocenters with photon therapy (e.g., 2D, 3D, or IMRT) or a single-isocenter photon therapy (e.g., 3D or IMRT) with active motion management, or total skin electrons, or mixed-electron/photon field(s), including imaging guidance, when performed.
77520
Proton treatment delivery; simple, without compensation.
77522
Proton treatment delivery; simple, with compensation.
77523
Proton treatment delivery; intermediate.
77525
Proton treatment delivery; complex.
Applicable CPT codes (added)CPTCovered
77407
Radiation treatment delivery, intermediate
77412
Radiation treatment delivery, complex
Applicable CPT/HCPCS codes (removed)mixed
77385
77386
G6015
G6016
G6017
Applicable CPT Codes (added)CPT
77407
radiation treatment delivery, intermediate
77412
radiation treatment delivery, complex
CPT/HCPCS Codes Removedmixed
77385
removed from policy
77386
removed from policy
G6015
removed from policy
G6016
removed from policy
G6017
removed from policy
Billing level guidance — 77407 vs 77412
Billing codesStandard single‑isocenter IMRT/VMAT should be billed with CPT 77407; CPT 77412 is for multiple isocenters or single‑isocenter delivery with active motion‑management (Level 3).
Documentation requirement for 77412When CPT 77412 is reported, documentation must clearly describe the circumstances that justify Level 3 rather than Level 2 treatment delivery (examples: multiple isocenters used, active respiratory gating or other motion‑management that changed delivery workflow).
Examples of supporting documentationSimulation and planning reports showing multiple isocenters or motion‑management setup; physician narrative describing need for multiple isocenters or active motion control; IGRT/respiratory gating logs or device records; dose‑distribution prints and isocenter coordinates demonstrating separate isocenter plans.
Prior authorization noteMedical records documentation may be required to assess whether the member meets clinical criteria for coverage; documentation does not guarantee coverage.
Prior Authorization, Documentation, and Billing Guidance
Documentation Required
Prior Authorization, Documentation, and Billing Guidance
This Medical Policy applies to Ohio. Requests for services stated as unproven or services subject to coverage or quantity limits will be evaluated for medical necessity using Ohio Administrative Code 5160-101. UnitedHealthcare uses InterQual for primary medical/surgical criteria; if InterQual lacks applicable criteria, internal UnitedHealthcare criteria or other externally approved guidelines may be used. Documentation that fully supports medical necessity may be requested and lack of such documentation may result in denial or noncoverage.
The patient's medical record must contain documentation that fully supports the medical necessity for the requested services (eg, relevant history, physical exam, diagnostic test results).
Medical records documentation may be required to assess whether the member meets clinical criteria for coverage but does not guarantee approval.
When advanced delivery CPT 77412 is reported, documentation must clearly describe the circumstances that justify level 3 (eg, multiple isocenters or single-isocenter with active motion management).
Standard single-isocenter IMRT/VMAT should be billed under CPT 77407; use CPT 77412 for multiple-isocenter or single-isocenter with active motion-management techniques.
IMRT should not routinely substitute for brachytherapy for central disease in intact cervix patients; documentation should justify modality selection.
Prior authorization should specify treatment technique, clinical indication, and image-guidance/motion-management approaches when applicable.
Background and Evidence Summary
Intensity-modulated radiation therapy (IMRT) is an advanced, high-precision external-beam radiation technique that modulates beam intensity across multiple beamlets to conform dose to a three-dimensional target while sparing adjacent normal tissues. IMRT and related technologies (including volumetric-modulated arc therapy and associated image-guided techniques) are commonly used across many tumor sites — for example, central nervous system, head and neck, breast, prostate, gastrointestinal, thoracic, and gynecologic cancers — when improved target conformity and organ-at-risk sparing are required. Use of IMRT typically requires CT-based simulation, IMRT-specific planning (including dose–volume histogram evaluation), and image-guided radiation therapy during delivery to ensure accurate targeting.
Definitions and Abbreviations
Definitive Therapy — definition
DefinitionDefinitive Therapy: radiation treatments for cancer with curative intent.
Scope implicationUsed throughout the policy to denote treatments intended to cure the primary cancer site rather than palliative care.
Reference sourcesDefinition cited to NCCN (2025) and National Cancer Institute conceptualization of curative‑intent therapy.
DP‑IMRT — definition and context
DefinitionDose‑painted IMRT (DP‑IMRT): IMRT with differential dosing to target volumes based on stage/size; used in RTOG 0529 for anal cancer to tailor dose to tumor and nodal volumes.
Context of useDP‑IMRT was applied in RTOG 0529 with specified dose levels (eg, 50.4–54 Gy to primary tumor and involved nodes; lower doses to elective nodes) to reduce toxicity while maintaining control.
Policy Changes and Revision History
2026-05-01billing_codes_update
Added CPT codes 77407 and 77412 to Applicable Codes and removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017; added billing guidance distinguishing when to use 77407 vs 77412 and documentation expectations when 77412 is reported.
2026-05-01documentation_requirementLatest
Added explicit language that medical records documentation may be required to assess whether the member meets clinical criteria and must fully support medical necessity (including history, exam, and pertinent test results), noting documentation does not guarantee coverage.
Change TypeMaterial revisions to covered indicationscoding and documentation updates
Effective DateMay 1, 2026
Next Review DateN/A
Key ActionWhen requesting authorization, specify treatment technique, indication, and image-guidance and include medical record documentation that supports medical necessity.
Strength of recommendation: strong for many indications.
Gynecologic and cervical cancer: Randomized and meta-analytic data (PARCER, Padhi, meta-analyses) show that IMRT/IGRT reduces acute and late GI/GU and hematologic toxicities compared with 3D-CRT while maintaining tumor control; guidelines (ASTRO, ESGO/ESTRO/ESP, NCCN) prefer IMRT for pelvic radiation but note IMRT should not routinely replace brachytherapy for central disease.
PARCER: substantial reduction in grade ≥2 late GI toxicity with IG-IMRT vs 3D-CRT.
When IMRT preferred vs 3D-CRT: IMRT is preferred when conformality is required to spare OARs, in para-aortic nodal treatment, for gross nodal disease requiring high dose, and when 3D-CRT cannot meet dose constraints to critical structures.
Guideline and trial-based rationale
BED > 80.5 Gy
MD Anderson retrospective and ASTRO guideline
Hippocampal-avoidance WBRT: HA-WBRT plus memantine is recommended for patients receiving WBRT who have no metastases within the hippocampal-avoidance region and expected survival ≥ 4 months; HA-WBRT reduces cognitive failure versus standard WBRT with memantine.no hippocampal lesions; expected survival >= 4 months
NRG CC001 and guideline references
Thymic and thyroid tumors:
Observational data support postoperative radiotherapy benefit in thymoma/thymic carcinoma; IMRT is recommended/preferred for thyroid cancers in guidelines despite limited high-quality evidence.
NCCN and systematic review references
Limited‑disease SCLC: Retrospective data suggest dose-escalated once-daily IMRT regimens with BED10 > 70 Gy may improve OS and in-field control without increasing pneumonitis in selected patients; evidence is limited and retrospective.BED10 > 70 Gy
Yang et al. single-institution retrospective analysis; interpret cautiously.
NCCN and ASTRO guidance; emphasized for vulvar and thoracic tumors.
Dose-escalation context: Dose-escalated once-daily IMRT regimens achieving BED10 > 70 Gy have retrospective data suggesting improved OS and local control in limited-disease SCLC without significantly increased pneumonitis in one series—use cautiously due to limited evidence.BED10 > 70 Gy
Yang et al. retrospective cohort.
IMRT fraction count for HCC inclusion
Fraction count requirementIMRT regimens included in the HCC evidence base were delivered in at least 10 fractions (studies required ≥10 fractions for inclusion).
Implication for coverageFor unresectable HCC treated with IMRT, use of fractionation schedules of ≥10 fractions aligns with the studies cited in the policy.
Evidence sourceSystematic review/meta‑analysis criteria required inverse‑planned IMRT delivered in at least 10 fractions (Jang et al., 2023).
BED threshold for intrahepatic cholangiocarcinoma
BED thresholdA biologically effective dose (BED) > 80.5 Gy was associated with improved 3‑year local control and overall survival in unresectable intrahepatic cholangiocarcinoma.
Study contextMD Anderson single‑institution retrospective analysis of definitive RT (3D‑CRT, IMRT, or passive scatter proton) showed BED > 80.5 Gy correlated with better outcomes.
Planning implicationDose‑escalated regimens aiming for BED > 80.5 Gy should use advanced techniques (daily CT image guidance, breath‑hold gating) to safely deliver ablative doses while respecting OAR constraints.
HA‑WBRT dosing
Recommended dose/fractionationHA‑WBRT plus memantine: 30 Gy in 10 fractions (preferred per NCCN) when patient meets eligibility criteria.
Eligibility contextPreferred for patients with expected prognosis ≥4 months and no metastases within ~5 mm of the hippocampus or leptomeningeal disease.
Evidence basisSupported by randomized trials (NRG CC001/Brown et al.) demonstrating reduced cognitive failure with HA‑WBRT plus memantine versus WBRT plus memantine.
BED10 threshold (> 70 Gy) — limited‑disease SCLC
BED10 thresholdA BED10 > 70 Gy was used to define the dose‑escalated group in a retrospective limited‑disease SCLC study and was associated with improved OS and in‑field control.
Study specificsYang et al. (2023) categorized patients by BED10 of 70 Gy to compare standard versus dose‑escalated once‑daily IMRT concurrent chemoradiation outcomes.
Interpretation cautionFindings derive from retrospective data and should be interpreted cautiously when considering dose escalation; prospective validation is limited.
Hippocampal‑avoidance WBRT fraction limit
Fraction limit for HA‑WBRTPolicy states hippocampal‑avoidance WBRT is considered proven and medically necessary for up to 10 fractions when all listed criteria are met.
Preferred schedule per guidelinesNCCN preference: HA‑WBRT plus memantine 30 Gy in 10 fractions for eligible patients with prognosis ≥4 months and no hippocampal‑region metastases.
Coverage noteEligibility requires documentation (eg, imaging to exclude metastases near hippocampus) and expected prognosis; failure to meet criteria may affect appropriateness of HA technique.
Hypofractionated RT for Stage I–II NSCLC — fraction limit
Fractionation cap for hypofractionated RT in Stage I–II NSCLCPolicy lists Stage I–II NSCLC treated with hypofractionated RT up to 10 fractions as a proven/medically necessary scenario for IMRT delivery.
Guideline contextASTRO/ARS/NCCN recognize hypofractionated regimens (including SBRT‑style schedules) for early‑stage NSCLC; the policy explicitly allows IMRT hypofractionation up to 10 fractions for Definitive Therapy in Stage I–II disease.
Documentation implicationTreatment intent, fractionation schedule, and planning details should be documented to support use of hypofractionated IMRT in early‑stage NSCLC.
When IMRT/VMAT is selected to spare organs at risk (OARs) versus 3D techniques, clinical justification and dose-constraint considerations should be documented; mandatory trial of 3D-CRT is not required when IMRT is needed to meet dose constraints or reduce toxicity.
Image-guided radiation therapy (IGRT), appropriate simulation (eg, CT-based, 4D-CT, PET/CT), and motion-management strategies should be documented when required to safely deliver the planned technique.
Combined IMRT and proton beam therapy in a single treatment plan is not supported by current evidence and should be justified if proposed.
Lack of sufficient documentation to support medical necessity may result in denial or noncoverage.
Note
Provider Actions / Step Therapy
Provider actions explicitly not stated in this excerpt: none provided. No step therapy is specified in this section of the document.
Provider action: None explicitly stated in this excerpt.
Provider action: Not provided in this section of the document.
Provider action: No step therapy specified.
Billing Rule
Authorization and Coding Considerations
Prior authorization and supporting documentation expectations: when requesting authorization for advanced radiation techniques (eg, IMRT/VMAT, SBRT, PBRT), include disease-specific rationale referencing guideline recommendations when applicable, description of target volumes and OAR constraints, image-guidance and motion-management plans, and any simulation or quality-assurance measures required for safe delivery. For billing and coding, follow CPT guidance for treatment delivery level (77407 vs 77412) and retain records that justify the selected code level.
Include guideline-based justification when IMRT is requested to minimize dose to critical organs (eg, head & neck, thoracic, pelvic, breast reconstructions, hepatic tumors).
Specify whether daily image guidance (eg, cone-beam CT) or other IGRT methods will be used for verification.
When requesting complex delivery (CPT 77412), provide documentation examples demonstrating multiple isocenters or active motion-management and why level 3 delivery is required.
Ensure simulation and treatment planning documentation (eg, CT/4D-CT/PET-CT, target/OAR contours, dose–volume histograms, motion management records) are available for review.
Denial Risk
Denial Risk: Documentation Insufficiency
Denial risk: insufficient or missing medical record documentation to support medical necessity, lack of justification for advanced techniques over 3D-CRT when required, or failure to document eligibility criteria for specialized approaches (eg, hippocampal-avoidance WBRT eligibility) may result in denial or noncoverage.
Provide clear documentation that there are no metastases within 5 mm of the hippocampus and that prognosis meets guideline expectations when requesting hippocampal-avoidance WBRT.
Failure to provide requested records or adequate clinical rationale for modality selection (including why 3D-CRT cannot meet dose constraints) may lead to denial.
Implication for planningRequires detailed target delineation and DVH reporting to support differential dose levels across PTV subvolumes.
APBI‑IMRT — definition
DefinitionAPBI‑IMRT: accelerated partial‑breast irradiation delivered using IMRT techniques, typically shorter fractionation targeting the tumor bed only (eg, 30 Gy in 5 fractions in Florence trial).
Clinical evidenceFlorence APBI‑IMRT trial used 30 Gy in five fractions and demonstrated low 10‑year ipsilateral breast tumor recurrence and reduced acute/late toxicity in selected low‑risk patients.
Patient selection noteAPBI‑IMRT is appropriate for selected early‑stage, low‑risk patients per guideline and trial inclusion criteria; technique and fractionation affect outcomes and cosmesis.
IMRT‑DIBH — definition and context
DefinitionIMRT‑DIBH: IMRT delivered with deep inspiration breath‑hold to reduce cardiac dose for left‑sided breast cancer, particularly when internal mammary nodes are targeted.
EvidenceRandomized data (Jagsi et al.) showed lower mean heart and LAD doses and potential preservation of left ventricular ejection fraction with IMRT‑DIBH versus standard RT.
Implementation noteDIBH requires dedicated simulation, patient training, and documentation of breath‑hold reproducibility and dosimetry to support technique selection.
DIBH — definition
DefinitionDeep inspiration breath‑hold (DIBH): patient breath‑hold technique that increases heart–lung separation to reduce cardiac and pulmonary dose during thoracic or left‑sided breast RT.
Use casesRecommended in PMRT and left‑sided breast treatments when it reduces heart/lung dose compared with free breathing.
Operational noteRequires reproducible breath‑hold capability, simulation with breath‑hold CT, and documentation of dose reductions achieved.
IMRT/VMAT — definition
DefinitionIMRT/VMAT: highly conformal photon‑based techniques that deliver nonuniform beam intensities (IMRT) or rotational arc delivery (VMAT) to optimize target coverage and spare organs at risk.
Technical noteOften used with image guidance (IGRT), motion management (eg, DIBH, gating), and advanced simulation (4D‑CT, PET/CT) for complex thoracic, mediastinal, or head‑and‑neck cases.
Clinical rationalePreferred when 3D‑CRT cannot meet target coverage or OAR constraints; may increase low‑dose exposure to surrounding tissues, requiring careful dose‑constraint adherence.
IGRT — definition
DefinitionIGRT: use of orthogonal or volumetric imaging (eg, cone‑beam CT) at the time of treatment delivery to ensure accurate target localization and margin reduction.
Required whenRecommended for IMRT delivery to verify daily setup, account for interfraction motion, and support safe OAR sparing—particularly for pelvic and thoracic treatments.
DocumentationDaily IGRT records and simulation imaging should be available to support justification of advanced techniques during prior authorization or medical record review.
DefinitionImage‑guided radiation therapy (IGRT): use of imaging (orthogonal or volumetric such as cone‑beam CT) at treatment delivery to ensure accurate targeting and allow margin reduction when delivering IMRT.
Clinical roleEssential for pelvic/gynecologic IMRT, HA‑WBRT, and thoracic deliveries where organ motion or setup variability can affect target coverage and OAR doses.
Supportive evidenceGuidelines (NCCN, ASTRO, ESGO) recommend IGRT with IMRT to ensure safe dose application and treatment verification.
Dysphagia‑optimized IMRT (DO‑IMRT)
DefinitionDysphagia‑optimized IMRT (DO‑IMRT): an IMRT planning approach that specifically reduces dose to pharyngeal constrictor muscles and other swallowing‑related structures to improve long‑term swallowing function.
Clinical evidenceDO‑IMRT RCT (Nutting et al.) showed improved MDADI scores at 12 and 24 months compared with standard IMRT, indicating better patient‑reported swallowing outcomes.
Planning implicationRequires contouring of dysphagia structures and dose‑prioritization during inverse planning to spare pharyngeal constrictors while maintaining target coverage.
DO‑IMRT — definition
DefinitionDO‑IMRT: dysphagia‑optimized intensity‑modulated radiation therapy that reduces dose to dysphagia‑ and aspiration‑related structures to improve swallowing outcomes and reduce related toxicities.
EvidenceRandomized trial evidence supports improved patient‑reported swallowing function and reduced toxicity compared with standard IMRT in select head‑and‑neck cancers.
Clinical useConsider DO‑IMRT when significant risk of long‑term dysphagia exists and when OAR sparing can be achieved without compromising tumor coverage.
IMRT fractionation — overview
Fractionation variabilityIMRT fractionation varies by indication; HCC cohorts in the evidence base typically used regimens delivered in ≥10 fractions.
Policy examplesPolicy explicitly lists Stage I–II NSCLC hypofractionated RT up to 10 fractions as an allowed definitive scenario, illustrating inclusion of both conventional and hypofractionated regimens.
Planning noteFractionation selection should be documented along with rationale, liver function (for HCC), and OAR constraints when deviating from conventional schedules.
OARs — definition and examples
DefinitionOrgans at risk (OARs): critical normal structures (eg, parotid glands, cochlea, optic structures, brainstem, spinal cord, heart, lungs, bowel) for which dose constraints are applied during planning to minimize toxicity.
Policy relevanceIMRT/VMAT is indicated when sparing of OARs is necessary to avoid clinically meaningful toxicity that cannot be achieved with 3D‑CRT.
DefinitionHA‑WBRT: whole‑brain radiation therapy planned to minimize dose to the hippocampal region (typically with a 3–7 mm avoidance margin) to preserve cognitive function; often delivered with memantine.
Clinical criteriaPreferred schedule is 30 Gy in 10 fractions with memantine for patients with prognosis ≥4 months and no metastases within 5 mm of the hippocampus; eligibility requires imaging to exclude hippocampal‑region disease.
EvidenceRandomized trials (NRG CC001/Brown et al., Gondi et al.) demonstrated reduced cognitive failure with HA‑WBRT plus memantine versus WBRT plus memantine.
IMRT/VMAT — conformal photon techniques
DefinitionIMRT/VMAT: conformal photon‑based techniques delivering nonuniform beam intensities (IMRT) or rotational arc delivery (VMAT) to optimize target coverage and spare OARs.
Clinical noteThese techniques often require IGRT and motion management and may increase low‑dose exposure to surrounding tissues; careful dose‑constraint adherence is required.
Guideline supportNCCN, ILROG, and specialty society guidelines endorse IMRT/VMAT when they improve the therapeutic ratio over 3D‑CRT for specific tumor sites.
3D‑CRT — definition
Definition3D‑CRT: CT‑based three‑dimensional conformal radiation therapy; considered a minimum standard for some thoracic and mediastinal malignancies.
RoleWhen 3D‑CRT cannot meet target coverage or OAR constraints, IMRT/VMAT is recommended; minimum simulation standard for thymomas/thymic carcinoma is CT‑based 3D‑CRT.
Planning implicationAdvanced imaging (4D‑CT, PET/CT) and motion management are appropriate when needed to safely deliver curative treatment beyond the 3D‑CRT minimum standard.
Modulated treatment techniques for pancreatic cancer (ASTRO guideline)
ContextASTRO guideline for localized pancreatic cancer recommends modulated treatment techniques (IMRT/VMAT) for planning and delivery to improve conformality and reduce GI toxicity.
ImplicationIMRT/VMAT are recommended when anatomical complexity and proximity to OARs make conformal dose delivery with 3D‑CRT suboptimal.
Supporting evidenceRetrospective and guideline evidence indicate lower acute GI toxicity with IMRT versus 3D‑CRT in pancreatic CRT cohorts.
Moderately hypofractionated, image‑guided IMRT — example
Example scheduleModerately hypofractionated, image‑guided IMRT (eg, regimens used in prostate cancer trials) — demonstrates comparable effectiveness and safety to conventional schedules when appropriately selected.
Clinical roleModerately hypofractionated IMRT is an accepted option in prostate cancer and illustrates that IMRT can be delivered with larger fraction sizes under image guidance.
DocumentationSimulation, IGRT approach, and fractionation rationale should be documented when using hypofractionated IMRT schedules.
BED10 — definition and use
DefinitionBED10: biologically effective dose calculated with α/β = 10, used to compare dose‑escalation regimens in thoracic SCLC analyses and to categorize dose‑escalated groups.
ApplicationBED10 thresholds (eg, >70 Gy) were used in retrospective SCLC studies to define dose‑escalated cohorts associated with improved outcomes.
CaveatBED10 comparisons across fractionation schemes require careful conversion and clinical judgment; retrospective findings need prospective validation.
OAR — definition
DefinitionOAR: organ at risk — critical normal tissues for which dose constraints are applied during planning to minimize acute and late toxicity.
ExamplesHeart, lungs, spinal cord, bowel, kidneys, liver, parotid glands, cochlea, optic apparatus, pharyngeal constrictors, bladder, and bone marrow.
Planning relevanceSelection of IMRT/VMAT is often driven by the need to meet OAR constraints that cannot be met with simpler techniques.
Definition change — Definitive Therapy
Change notePolicy updated the Definition of 'Definitive Therapy' — text updated in the Definitions section of the policy (specific revised wording located in policy body).
ImplicationDefinition refinement clarifies that Definitive Therapy refers to curative‑intent radiation for the primary site and informs which indications are classified as proven/medically necessary.
ReferenceSee Policy History/Revision Information (05/01/2026) for summary of changes to the Definitive Therapy definition.
Definitive Therapy — updated definition (notice)
Updated definition noticeThe policy updated the 'Definitive Therapy' definition; specific updated text is included in the policy body (refer to Definitions section of the full policy).
Administrative noteThis revision is part of the 05/01/2026 policy changes that also added multiple proven indications and billing guidance (CPT 77407, 77412).
Document locationSee Policy History/Revision Information for details of the update and the Definitions section for the revised wording.